Skip to main content
Signal8
Launch Terminal

Abivax S.A. (ABVX)

Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Abivax S.A. logo

Abivax S.A.

NASDAQ:ABVXHealthcare
-2.77%$86.59
AH$87.03+0.51%vs close
Mkt Cap$7.58B
Float77.44M
O/S87.54M
Vol
$ Vol
RVOL
Inst Own63.3%
SI9.4%
Earnings
Dilution
Abivax S.A. logoNASDAQ:ABVX$86.59-2.77%
Phase Distribution
23 lead-sponsored trials·4 active·17 completed
Phase 15
Phase 1/22
Phase 210
Phase 2/33
Phase 33
Status Overview
Recruiting2
Active, not recruiting2
Completed17
Stopped2

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 3
    Completed

    ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

    ABX464, Placebo

    Ulcerative Colitis

    Enrollment
    639
    Start
    Nov 2022
    Primary Completion
    Jun 2025
    Completion
    Jun 2025
    NCT05507203
  • Phase 3
    Completed

    ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

    ABX464, Placebo

    Ulcerative Colitis

    Enrollment
    636
    Start
    Jan 2023
    Primary Completion
    Jun 2025
    Completion
    Jul 2025
    NCT05507216
  • Phase 3
    Active, not recruiting

    ABTECT - Maintenance

    ABX464, Placebo

    Ulcerative Colitis

    Enrollment
    1,116
    Start
    Jan 2023
    Primary Completion
    Apr 2026
    Completion
    May 2030est.
    NCT05535946
  • Phase 2/3
    Completed

    Clinical Efficacy of ABX203 Therapeutic Vaccine in HBeAg Negative Patients With Chronic Hepatitis B

    ABX203 therapeutic Hepatitis B vaccine treatment arm

    Chronic Hepatitis B

    Enrollment
    261
    Start
    Dec 2014
    Primary Completion
    Dec 2016
    Completion
    Dec 2016
    NCT02249988
  • Phase 2/3
    Withdrawn

    Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease Patients

    ABX464, Placebo

    Crohn Disease

    Enrollment
    0
    Start
    Sep 2022est.
    Primary Completion
    Sep 2022est.
    Completion
    Sep 2022est.
    NCT03905109
  • Phase 2/3
    Terminated

    ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19

    ABX464, Placebo

    COVID-19

    Enrollment
    509
    Start
    Jul 2020
    Primary Completion
    Mar 2021
    Completion
    Apr 2021
    NCT04393038
  • Phase 2
    Completed

    Safety, PK and PD Study of ABX464 in Untreated HIV Patients

    ABX464

    Human Immunodeficiency Virus Infections

    Enrollment
    70
    Start
    Jan 2015
    Primary Completion
    Dec 2015
    Completion
    May 2016
    NCT02452242
  • Phase 2
    Completed

    ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment

    ABX464, Placebo

    HIV Infection

    Enrollment
    30
    Start
    May 2016
    Primary Completion
    Aug 2017
    Completion
    Jan 2018
    NCT02735863
  • Phase 2
    Completed

    ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis

    ABX464, Placebo oral capsule

    Ulcerative Colitis

    Enrollment
    32
    Start
    Nov 2017
    Primary Completion
    Jul 2018
    Completion
    Feb 2019
    NCT03093259
  • Phase 2
    Completed

    Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis

    ABX464

    Ulcerative Colitis

    Enrollment
    22
    Start
    Jan 2018
    Primary Completion
    Jul 2022
    Completion
    Aug 2022
    NCT03368118
  • Phase 2
    Completed

    Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis

    ABX464 100 mg, ABX464 50 mg

    Ulcerative Colitis

    Enrollment
    355
    Start
    Aug 2019
    Primary Completion
    Apr 2021
    Completion
    Apr 2021
    NCT03760003
  • Phase 2
    Completed

    Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis

    ABX464 50mg, Matching Placebo

    Rheumatoid Arthritis

    Enrollment
    60
    Start
    Jul 2019
    Primary Completion
    Apr 2021
    Completion
    Apr 2021
    NCT03813199
  • Phase 2
    Completed

    Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis

    ABX464

    Ulcerative Colitis

    Enrollment
    217
    Start
    Jan 2020
    Primary Completion
    Feb 2023
    Completion
    Feb 2023
    NCT04023396
  • Phase 2
    Completed

    Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis

    ABX464

    Rheumatoid Arthritis

    Enrollment
    40
    Start
    Oct 2019
    Primary Completion
    Jan 2023
    Completion
    Jan 2023
    NCT04049448
  • Phase 2
    Active, not recruiting

    Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis

    ABX464

    Ulcerative Colitis

    Enrollment
    203
    Start
    Dec 2021
    Primary Completion
    Mar 2028est.
    Completion
    Apr 2028est.
    NCT05177835
  • Phase 2
    Recruiting

    Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

    Obefazimod

    Moderately to Severely Active Crohn Disease

    Enrollment
    212
    Start
    Oct 2024
    Primary Completion
    Dec 2026est.
    Completion
    Apr 2028est.
    NCT06456593
  • Phase 1/2
    Completed

    A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults

    ABX464 150mg, ABX464 50mg

    HIV Infections, Health Volunteers

    Enrollment
    36
    Start
    Mar 2017
    Primary Completion
    Dec 2018
    Completion
    Oct 2019
    NCT02990325
  • Phase 1/2
    Completed

    ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma

    ABX196

    Carcinoma, Hepatocellular

    Enrollment
    10
    Start
    Feb 2020
    Primary Completion
    Apr 2022
    Completion
    Apr 2022
    NCT03897543
  • Phase 1
    Completed

    Food Effect on Pharmacokinetic Parameters of ABX464

    ABX464 Single dose, ABX464 Repeated dose

    Healthy Volunteers

    Enrollment
    48
    Start
    Sep 2014
    Primary Completion
    Jun 2015
    Completion
    Jun 2015
    NCT02731885
  • Phase 1
    Completed

    ABX464 First in Man Study

    ABX464

    Healthy Volunteers

    Enrollment
    24
    Start
    Mar 2014
    Primary Completion
    Jul 2014
    Completion
    Jul 2014
    NCT02792686
  • Phase 1
    Completed

    Safety and Pharmacokinetics Study in Healthy Japanese Volunteers

    ABX464, Placebo

    Healthy Volunteers

    Enrollment
    48
    Start
    Sep 2021
    Primary Completion
    Feb 2022
    Completion
    Feb 2022
    NCT05032560
  • Phase 1
    Completed

    Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464

    Caffeine, ABX464

    Healthy

    Enrollment
    59
    Start
    Dec 2020
    Primary Completion
    May 2021
    Completion
    May 2021
    NCT05121714
  • Phase 1
    Recruiting

    Study to Evaluate Pharmacokinetics, Relative Bioavailability, Palatability of Obefazimod Minitablet Formulation

    Obefazimod 50 mg Capsule, Obefazimod Minitablet 50 mg

    Healthy

    Enrollment
    44
    Start
    Mar 2026
    Primary Completion
    Sep 2026est.
    Completion
    Oct 2026est.
    NCT07453784
Search ClinicalTrials.gov for “Abivax”